EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Impact of CYP3A4 and ABCB1 genetic variants on tacrolimus dosing in Greek kidney transplant recipients

Anna Tsironi, Konstantinos Lazaros, Effrosyni Mendrinou, Marios Papasotiriou, Stavroula Siamoglou, Kyriaki Kydonopoulou, Anne John, Alexandra Gerou, Spyridon Gerou, Bassam R Ali, Aristidis G Vrahatis, George P Patrinos

Frontiers in Pharmacology · 19.03.2025 · 16

DOI: 10.3389/fphar.2025.1538432 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 19.03.2025. Verfasst von Anna Tsironi und 11 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Pharmacogenomics and Individualized Therapy, Division of Pharmacology and Biosciences, Department of Pharmacy, School of Health Science…. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: European Commission.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Tacrolimus, an approved first-line calcineurin inhibitor, is widely prescribed in organ transplantation to prevent allograft rejection. Its narrow therapeutic index requires precise management to achieve optimal dosing and to minimize adverse drug events (ADEs) while ensuring its therapeutic efficacy. Among several factors, genetic differences contribute significantly to the inter-individual and inter-ethnic variability in pharmacokinetics (PK) of tacrolimus in kidney transplant recipients. As a result, investigating the role of genetic variation in Greek transplant recipients becomes crucial to optimizing therapeutic strategies and enhancing the efficacy of immunosuppressive treatment. Hypothesis Genetic variants which are known to influence the activity of enzymes or drug-transporters critical to tacrolimus pharmacokinetics, may significantly affect the required kidney post-transplant tacrolimus daily dose.

Aim

To assess the correlation of ABCB1 genetic variants (rs1128503, rs2229109) and CYP3A4 (rs2242480, rs4986910) with tacrolimus dose-adjusted trough concentration (C 0 /D), in Greek kidney transplant recipients.

Methods

Ninety-four unrelated Greek kidney transplant recipients were included in this study from the Department of Nephrology and Kidney Transplantation of the University General Hospital of Patras. Patients’ dose-adjusted trough levels were measured at five distinct time points after transplantation and analyzed in relation to the possible influence of CYP3A4 and correlated with the abovementioned ABCB1 genetic variants using standard genotyping analysis and Sanger sequencing.

Results

The genetic variants rs1128503, rs2229109, rs2242480, rs4986910 did not show any significant association with the daily dosing requirements of tacrolimus for at least 1 year, in Greek patients who have undergone kidney transplant.

Conclusion

It remains uncertain whether these genetic variants influence the assessment of the appropriate tacrolimus dosing 1 year after transplantation in Greek kidney transplant recipients.

Schlagwörter

Stichwörter der Autor:innen

C/D ratioFK506Greek populationkidney transplantationtacrolimus

Autor:innen und Institutionen

  • Laboratory of Pharmacogenomics and Individualized Therapy, Division of Pharmacology and Biosciences, Department of Pharmacy, School of Health Sciences, University of Patras, Patras, Greece.
  • Department of Informatics, Ionian University, Corfu, Greece.
  • Molecular Diagnostics Laboratory, INRASTES, National Centre for Scientific Research "Demokritos", Athens, Greece.
  • Department of Nephrology and Kidney Transplantation, University Hospital of Patras, Patras, Greece.
  • ANALYSI Biomedical Laboratories S.A., Thessaloniki, Greece.
  • Department of Genetics and Genomics, College of Medicine and Health Sciences, United Arab Emirates University, Al-Ain, United Arab Emirates.

Förderung

  • European Commission

Zitieren

APA

Tsironi, A., Lazaros, K., Mendrinou, E., Papasotiriou, M., Siamoglou, S., Kydonopoulou, K., John, A., Gerou, A., Gerou, S., Ali, B. R., Vrahatis, A. G., & Patrinos, G. P. (2025). Impact of CYP3A4 and ABCB1 genetic variants on tacrolimus dosing in Greek kidney transplant recipients. Frontiers in Pharmacology, 16. https://doi.org/10.3389/fphar.2025.1538432

Vancouver

Tsironi A, Lazaros K, Mendrinou E, Papasotiriou M, Siamoglou S, Kydonopoulou K, et al. Impact of CYP3A4 and ABCB1 genetic variants on tacrolimus dosing in Greek kidney transplant recipients. Frontiers in Pharmacology. 2025;16. doi:10.3389/fphar.2025.1538432

BibTeX
@article{Tsironi2025,
  author = {Tsironi, Anna and Lazaros, Konstantinos and Mendrinou, Effrosyni and Papasotiriou, Marios and Siamoglou, Stavroula and Kydonopoulou, Kyriaki and John, Anne and Gerou, Alexandra and Gerou, Spyridon and Ali, Bassam R and Vrahatis, Aristidis G and Patrinos, George P},
  title = {Impact of CYP3A4 and ABCB1 genetic variants on tacrolimus dosing in Greek kidney transplant recipients},
  journal = {Frontiers in Pharmacology},
  year = {2025},
  volume = {16},
  doi = {10.3389/fphar.2025.1538432}
}
Kostenlos starten →